Bavarian Nordic
BiotechBavarian Nordic is a biotechnology company focused on Infectious Disease, Oncology. Key products include Vaxchora.
Bavarian Nordic at a Glance
- Fast trial execution (16 months median completion)
Bavarian Nordic's Key Drugs
Bavarian Nordic's core commercial portfolio centers on Vaxchora, Jynneos, VIMKUNYA, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.
Bavarian Nordic's Recent FDA Approvals
Bavarian Nordic secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Bavarian Nordic's Therapeutic Areas
Bavarian Nordic's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Oncology, across 5 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Bavarian Nordic's Top Competitors
Bavarian Nordic's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Bavarian Nordic Pipeline Snapshot
Bavarian Nordic has 15 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 4 Phase 2 and 8 Phase 1.
Phase 3 Readout Calendar Pro
3 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Vaxchora leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • 3 Phase 3 readouts tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 10/14 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges